PD-1/PD-L1: A novel target for immunotherapy in patients with advanced and metastatic non-small cell lung cancer
Immune checkpoints are receptor-ligand interactions that either enhance or turn down the activation of T-lymphocytes. Among them, the interaction of Programmed death receptor-1 (PD-1) and Programmed death ligand-1 (PD-L1) shows suppressive effect of T-lymphocytes, preventing over activation of T-lym...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Belgrade, Medical Faculty
2018-01-01
|
| Series: | Medicinski Podmladak |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/0369-1527/2018/0369-15271802057S.pdf |